11,858 reports of this reaction
3.8% of all TREPROSTINIL reports
#4 most reported adverse reaction
NAUSEA is the #4 most commonly reported adverse reaction for TREPROSTINIL, manufactured by United Therapeutics Corporation. There are 11,858 FDA adverse event reports linking TREPROSTINIL to NAUSEA. This represents approximately 3.8% of all 313,927 adverse event reports for this drug.
TREPROSTINIL has an overall safety score of 85 out of 100. Patients taking TREPROSTINIL who experience nausea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NAUSEA is moderately reported among TREPROSTINIL users, representing a notable but not dominant share of adverse events.
In addition to nausea, the following adverse reactions have been reported for TREPROSTINIL:
The following drugs have also been linked to nausea in FDA adverse event reports:
NAUSEA has been reported as an adverse event in 11,858 FDA reports for TREPROSTINIL. This does not prove causation, but indicates an association observed in post-market surveillance data.
NAUSEA accounts for approximately 3.8% of all adverse event reports for TREPROSTINIL, making it a notable side effect.
If you experience nausea while taking TREPROSTINIL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.